NCT02875366View on ClinicalTrials.gov

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

October 31, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

LUM/IVA

DRUG

Placebo

Trial Locations (12)

Unknown

Melbourne

Parkville

Adelaide

Camperdown

Clayton

Nedlands

New Lambton Heights

Randwick

South Brisbane

Subiaco

Westmead

Edinburgh

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02875366 - A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation | Biotech Hunter | Biotech Hunter